We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+3.44%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$938M
AUM Growth
-$133M
Cap. Flow
-$102M
Cap. Flow %
-10.88%
Top 10 Hldgs %
63.92%
Holding
49
New
11
Increased
10
Reduced
7
Closed
14

Top Buys

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$53.6M
2
AFMD
Affimed
AFMD
+$39M
3
NKTX icon
Nkarta
NKTX
+$27.2M
4
LEGN icon
Legend Biotech
LEGN
+$24.5M
5
SWTX
SpringWorks Therapeutics
SWTX
+$24.1M

Top Sells

Rank Stock Value
1
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
+$71.3M
2
GNMK
GenMark Diagnostics, Inc
GNMK
+$65.4M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$38.2M
4
MRSN
Mersana Therapeutics
MRSN
+$37.3M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$32.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.03%
2 Financials 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLRB icon
26
Cellectar Biosciences
CLRB
$20.5M
$6.56M 0.7%
13,580
– –
IMGN
27
DELISTED
Immunogen Inc
IMGN
$5.7M 0.61%
703,790
-2,812,154
-80% -$23M
SLN
28
Silence Therapeutics
SLN
$564M
$5.11M 0.54%
+222,222
New +$5.41M
RACB
29
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$3.08M 0.33%
+300,000
New +$3.07M
DFHTU
30
DELISTED
Deerfield Healthcare Technology Acquisitions Corp. Unit
DFHTU
$3.01M 0.32%
229,800
-20,200
-8% -$293K
MSACU
31
DELISTED
Medicus Sciences Acquisition Corp. Unit
MSACU
$2.96M 0.32%
+300,000
New +$3.05M
JYAC
32
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.95M 0.31%
300,000
– –
ARYD
33
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$2.62M 0.28%
+250,000
New +$2.7M
TNGX icon
34
Tango Therapeutics
TNGX
$4.41B
$2M 0.21%
180,000
– –
MLTX icon
35
MoonLake Immunotherapeutics
MLTX
$1.55B
$1.53M 0.16%
150,000
– –
ADMA icon
36
ADMA Biologics
ADMA
$2.22B
– –
-1,558,290
Closed -$3.04M
AGIO icon
37
Agios Pharmaceuticals
AGIO
$1.93B
– –
-631,215
Closed -$27.4M
ASMB icon
38
Assembly Biosciences
ASMB
$529M
– –
-164,156
Closed -$11.9M
ATNM icon
39
Actinium Pharmaceuticals
ATNM
$25M
– –
-88,428
Closed -$690K
COGT icon
40
Cogent Biosciences
COGT
$7.24B
– –
-610,000
Closed -$6.85M
MRSN
41
DELISTED
Mersana Therapeutics
MRSN
– –
-56,068
Closed -$37.3M
RCUS icon
42
Arcus Biosciences
RCUS
$3.64B
– –
-387,492
Closed -$10.1M
YMAB
43
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-6,073
Closed -$301K
CERE
44
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-39,697
Closed -$658K
ISEE
45
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-2,373,924
Closed -$16.4M
TCRR
46
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-584,885
Closed -$71.3M
KDMN
47
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-7,349,621
Closed -$30.5M
GNMK
48
DELISTED
GenMark Diagnostics, Inc
GNMK
– –
-4,480,163
Closed -$65.4M
FSDC
49
DELISTED
FS Development Corp. Class A Common Stock
FSDC
– –
-100,000
Closed -$1.1M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Consonance Capital Management held 49 positions worth $938M, down 12% from $1.07B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Consonance Capital Management withdrew a net $102M in Q1 2021, closing 14 positions and reducing 7 holdings. Its most notable exit was TCR2 Therapeutics Inc. Common Stock, an estimated $71.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Financials.

Against the trend, Consonance Capital Management opened a new position in Turning Point Therapeutics, Inc. Common Stock worth $42.6M.

  • Consonance Capital Management's largest Q1 2021 buy was Turning Point Therapeutics, Inc. Common Stock: 450,396 shares worth $42.6M.
  • Consonance Capital Management added most to SpringWorks Therapeutics in Q1 2021, an estimated $24.1M increase.
  • Consonance Capital Management's biggest Q1 2021 reduction was Iovance Biotherapeutics, cutting an estimated $38.2M.
  • Consonance Capital Management fully exited TCR2 Therapeutics Inc. Common Stock in Q1 2021, selling an estimated $71.3M.
  • Consonance Capital Management's ten largest holdings make up 64% of its $938M portfolio in Q1 2021.
  • Consonance Capital Management opened 11 new positions and closed 14 in Q1 2021.
  • Consonance Capital Management's portfolio value fell 12% quarter-over-quarter to $938M.

Based on Consonance Capital Management's 13F filing for Q1 2021, filed 17 May 2021.